Brightstar Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Brightstar Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Brightstar Study Today - Breaking & Trending Today

BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC

Published: October 6, 2023

Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.

Source: onclive.com

Related Topics:

Yasir ElaminLocal Consolidative TherapyTyrosine Kinase Inhibitor NaRearranged MetastaticNon Small Cell Lung CancerLung CancerMetastatic NsclcMetastatic Lung CancerBrightstar TrialBrightstar StudyTyrosine Kinase InhibitorTyrosine Kinase InhibitionStudy DesignTrial DesignPatient CharacteristicsEfficacy DataSafety DataConsolidation TherapyPfs DataProgression Free Survival